The abstract is read at the publisher; the summary is JClub's.
Adjuvant pembrolizumab after surgery in high-recurrence clear cell renal cell carcinoma shows sustained disease-free survival benefit (HR 0.71) and improved overall survival (HR 0.66) at 5 years.
- Why it matters: The study addresses the need for durable adjuvant therapy after nephrectomy to reduce recurrence and improve long-term survival in patients with clear cell renal cell carcinoma at increased risk.
- What they did: In KEYNOTE-564, 994 adults were randomized 1:1 to pembrolizumab 200 mg every 3 weeks or placebo for up to 17 cycles, with DFS as the primary endpoint and OS as a key secondary endpoint.
- The result: With a median follow-up of 70 months, estimated 5-year DFS was 60.9% vs 52.2% and 5-year OS was 87.7% vs 82.3%, with benefits consistent across subgroups and safety largely unchanged.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.